Bart Leroy, EURETINA 2022: RNA Interference Therapy for CEP290-IRD
Prof. Bart Leroy (Ghent University, Ghent, Belgium) joined touchOPHTHALMOLOGY in an interview to speak about RNA interference therapy and its advantages in treating inherited retinal diseases caused by CEP290 mutations.
‘RNA Interference Therapy for CEP290-IRD’ was presented at EURETINA 2022, 1–4 September 2022
- Could you tell us a little about inherited retinal diseases (IRD) caused by CEP290 mutations and the unmet needs in their treatment? (00:22)
- Could you explain the mechanism of action of RNA interference therapy? (02:20)
- What are the advantages and limitations of this strategy compared with other gene therapies in IRD? (05:48)
- What clinical evidence supports the use of RNA interference therapy? (08:02)
- What questions remain unanswered and what future studies are planned? (12:27)
Disclosures: Bart Leroy is a consultant for and receives grant/research support from ProQR Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of EURETINA 2022.
Share this Video
Related Videos In Retina/Vitreous
David Boyer, ARVO 2023: Phase IIb RESTORE trial: MCO-010 optogenetic therapy for vision restoration in patients with retinitis pigmentosa
The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical […]
David Boyer, ARVO 2023: Retinitis Pigmentosa and the unmet needs in its treatment
Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around Retinitis Pigmentosa […]
Carl Regillo, Hawaiian Eye and Retina 2023: New and emerging treatments for neovascular age-related macular degeneration
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes with durability, which is one of the biggest unmet needs in treatment of age-related macular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!